The U.S. health care system saved $313 billion in 2019 from generics and biosimilar drugs, including $96 billion in Medicare savings and $48.5 billion in savings to Medicaid.
That was the headline in a report released earlier this week by the Association for Accessible Medicines (AAM).
The report stipulated that generics fill 90% of prescriptions in the United States for only 20% of the cost.
According to a press release, the title of this year’s report is "Securing Our Access & Savings."
"Even in the face of unprecedented challenges arising from a global pandemic, essential employees of generic and biosimilar manufacturers have been the unseen and unsung heroes, stepping up to deliver for America’s patients while continuing to alleviate economic pressures on the U.S. health care system,’’ said Dan Leonard, president and CEO of AAM. "Whether it be sedatives required for ventilation, steroids for treatment of COVID-19 or other critical applications, generic manufacturers continue to deliver essential drugs that will help save lives and serve as a bridge to a vaccine.’’
Alerts Sign-up